Prescription drug prices are a serious burden in America, and perhaps the chief modern example of why good intentions do not always equal solutions. Take the newly introduced Medication Affordability and Patent Integrity Act, sponsored by Sens. Maggie Hassan (D-NH) and Josh Hawley (R-MO).

Conceptually, it’s a modest transparency measure aimed at preventing contradictory statements to regulators. The bill would impose new certification and disclosure mandates on drug innovators when they interact with the FDA and U.S. Patent and Trademark Office.